膀胱癌经尿道电切除术后吡柔比星膀胱灌注预防复发临床观察

Intravesical instillation of pirarubicin for preventing the recurrence of bladder cancer after transurethral resect

目的:探讨吡柔比星膀胱内灌注预防膀胱癌术后复发的疗效、安全性。方法:45例膀胱癌经尿道电气化术后患者分2组,分别用吡柔比星和卡介苗定期行膀胱内灌注,随访10～33个月,了解灌注后肿瘤复发情况及并发症。结果:卡介苗组复发率为13.6%(3/22),副反应率为81.8%(18/22);吡柔比星复发率为13.0%(3/23),副反应率为91.3%(21/23),两组肿瘤复发率、并发症无显著差异,但卡介苗严重副反应高于吡柔比星(P<0.05)。结论:吡柔比星膀胱灌注预防膀胱癌复发的有效率与卡介苗相同,但严重副反应明显减少,是一种有效的药物。

To observe the efficacy and security intravesical instillation of pirarubicin for preventing the recurrence of bladder cancer after transurethral resect （TURBT）. Methods.. Forty-five postoperative patients with bladder cancer were divided into two groups to receive intravesical instillation of pirarubicin（THP） and Bacillus Calmette Guerin （BCG） respectively, once a week for six weeks, then once a month to one year. All the patients were followed up for 10--33 months, the tumor recurrence rate and the side effects associated with therapy were observed. Results.. The tumor recurrence rate of BCG groups were13.6 % （3/22）, side effects were81.8 % （18/ 22）, and the rate of THP were13.0% （3/23）, side effects were91.3% （21/23）. The tumor recurrence rate and side effects after intravesical instillation of two groups failed to show any significant change, but to the server side effects, the BCG groups was more than the THP. Conclusions： Intravesical instillation of THP for preventing postoperative recurrence of bladder cancer is effective and well tolerated. It is worth to spread in the clinical use.